Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

The Journal of Prevention of Alzheimer s Disease 2026 Open access

Read full text
Authors: Kristian Steen Frederiksen, Mercè Boada, Lutz Frölich, M. Kramberger, Nikolaos Scarmeas, Everard Vijverberg, Pieter Jelle Visser, Gunhild Waldemar, Eric Westman, Henrik Zetterberg, Sebastiaan Engelborghs, Frank Jessen
DOI: 10.1016/j.tjpad.2026.100598
Cited by: 3
References: 6

Abstract

Frederiksen, Kristian Steen; Boada, Mercè; Frölich, Lutz; Kramberger, Milica; Scarmeas, Nikolaos; Vijverberg, Everard; Visser, Pieter Jelle; Waldemar, Gunhild; Westman, Eric; Zetterberg, Henrik; Engelborghs, Sebastiaan; Jessen, Frank

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Alzheimer's disease research and treatments Vasculitis and related conditions

Publication details

Journal / source
The Journal of Prevention of Alzheimer s Disease
Publisher
Elsevier BV
Volume
13
Issue
7
Pages
100598–100598
Publication date
18 May 2026
Language
EN